Long title
A Phase 2a Randomized, Double-blind, Placebo-controlled rial to Assess the safety, Immunogenicity, and Efficacy of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Volunteers
Date receipt dossier
EudraCT number
2017-004582-27
Company / Sponsor
Bavarian Nordic A/S
Phase
IIa
Treated organism
Humans
Indication category
Infectious disease
Disease
Acute respiratory illness caused by RSV
Therapeutic approach
Prevention
Genetic modification
Vaccinia virus Ankara strain expression glycoproteins of different RSV strain (MVA-BN)
Method of transfer of nucleic acid of interest
not applicable
Administered biological material
Recombinant vaccinia virus (MVA-BN)
Route of administration
Intramuscular
Locations in Belgium
SGS Belgium NV
Type of procedure
Contained use only
Current status
Assessed